Abstract 1431P
Background
Neoadjuvant chemotherapy combined with immunotherapy (nCIT) is emerging as a promising strategy for treating patients with esophageal cancer. We aimed to develop a novel, voxel-level radiomics deep learning model to predict the pathological complete response (pCR) to nCIT in esophageal squamous cell carcinoma (ESCC).
Methods
We included 745 ESCC patients from three institutions, comprising a training set (N=500, institution 1), test-set-1 (N=86, institution 1), test-set-2 (N=34, institution 2), and test-set-3 (N=125, institution 3). All patients underwent nCIT and received a pathological evaluation post-surgery. A total of 104 distinct radiomic features were extracted from the tumor areas in CT images prior to nCIT. Features demonstrating predictive power with an area under the receiver operating characteristic curve (AUROC) exceeding 0.6 were retained. Each selected radiomics feature map, along with the original image, was input into a vision transformer model as a separate channel. The Shapley Additive exPlanations method was employed to visualize feature importance and identify predictive regions within the tumor, enhancing the model’s interpretability. For baseline comparison, we also constructed a clinical model using only clinical factors, and compared it against traditional radiomics and ResNet models.
Results
The voxel-level radiomics deep learning model achieved an AUC of 0.825 with an accuracy of 76.2% in test-set-1, 0.751 and 68.5% in test-set-2, and 0.819 with 78.1% in test-set-3, respectively. It demonstrated superior predictive performance compared to the clinical model, traditional radiomics model, and ResNet model.
Conclusions
This innovative and noninvasive voxel-level radiomics deep learning approach offers an efficient and accurate approach of predicting treatment response to nCIT in ESCC, potentially benefiting clinical decision-making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Z. Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1154P - Prospective multinational evaluation of alkylating-induced hypermutation in neuroendocrine neoplasms (NEN): Clinical and molecular profiles associated with response to immune checkpoint inhibitors (CPI)
Presenter: Elena Trevisani
Session: Poster session 17
1156P - The efficacy of lower doses of everolimus in patients with advanced neuroendocrine tumors
Presenter: Rachel Riechelmann
Session: Poster session 17
1157P - Retreatment with peptide receptor radionuclide therapy (PRRT) in patients (p) with neuroendocrine tumors (NET): Spanish clinical experience from SEPTRALU national registry
Presenter: Jorge Hernando Cubero
Session: Poster session 17
1158P - A novel nomogram for predicting overall survival of small intestinal neuroendocrine tumors treated with PRRT
Presenter: Dimitrios Papantoniou
Session: Poster session 17
1159P - Molecular characterization of extra-pulmonary mixed adeno-neuroendocrine carcinomas: The NIRVANA substudy
Presenter: Francesca Spada
Session: Poster session 17
1160P - An Italian multicenter phase II trial of metronomic temozolomide in unfit patients with advanced neuroendocrine neoplasms: Interim analysis of the MeTe study
Presenter: Francesca Spada
Session: Poster session 17
1161P - Progression-free survival ratio and the implications for treatment sequencing in neuroendocrine neoplasms
Presenter: Philipp Melhorn
Session: Poster session 17
1162P - Transcriptomic analysis of gastroenteropancreatic neuroendocrine tumours with carcinoid syndrome
Presenter: Javier Pozas Perez
Session: Poster session 17
1163P - Prognostic value of systemic inflammatory index (SII) in neuroendocrine tumors (NETs) treated with peptide receptor radionuclide therapy (PRRT)
Presenter: Eduardo Terán Brage
Session: Poster session 17